| Literature DB >> 30603000 |
Fatiu A Arogundade1, Akinwumi A Akinbodewa2, Abefe A Sanusi1, Oluyomi Okunola1, Muzamil O Hassan3, Adewale Akinsola1.
Abstract
INTRODUCTION: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is presumably rare in Africa. Knowledge about the disease in Nigeria is limited as demonstrated by scanty articles on the subject.Entities:
Keywords: Clinical presentation; Nigeria; autosomal dominant polycystic; kidney disease
Mesh:
Year: 2018 PMID: 30603000 PMCID: PMC6307032 DOI: 10.4314/ahs.v18i3.25
Source DB: PubMed Journal: Afr Health Sci ISSN: 1680-6905 Impact factor: 0.927
Parameters of ADPKD subjects in OAUTH Ile-Ife (1996–2010)
| PARAMETERS | MALE | FEMALE | ALL SUBJECTS |
| Age at presentation (years) | 43.4 (±15.7) | 46.3 (±14.3) | 48.6±4.6years |
| SBP (mmHg) | 162.8 (±26.7) | 172.2 (±18.3) | 166.9 ±23.6 |
| DBP (mmHg) | 104.7 (±23.6) | 104.4 (±18.5) | 104 ±21.2 |
| Sodium (mmol/L) | 133.2 (±5.9) | 135.5 (±3.8) | 134.2±5.1 |
| Potassium (mmol/L) | 4.8 (±1.1) | 4.4 (±0.9) | 4.5±1.0 |
| Bicarbonate (mmol/L) | 20.5 (±2.3) | 20.9 (±2.5) | 20.6±2.3 |
| Urea (mmol/L) | 18.8 (±9.9) | 20.5 (±14.0) | 19.5±11.7 |
| Creatinine (umol/L) | 707 (118–2413) | 484 (76–3722) | 614 (76–3722) |
| eGFR (ml/min) | 33.2 (±22.2) | 35.5 (±25.8) | 34.2±23.6 |
| Haematocrit (%) | 27.0 (±4.8) | 25.9 (±6.1) | 26.5±5.4 |
| TWCC | 5,472.6 (±2344.9) | 5,789.3 (±2412.5) | 5,611.6±2,350 |
| Platelet | 180,671.7 (±30,233) | 214,777.8 (±139,605.9) | 195,645.1±95286.6 |
| No of HD sessions | 5.4 (±5.0) | 6.0 (±5.2) | 5.6±5.0 |
| Duration of survival (mo) | 24.0 (±24.0) | 23.2 (±20.9) | 23.6±22.4 |
| Age at death (years) | 46.6±15.8 | 45.9±14.1 | 46.3±14.7 |
| Age of survivors (years) | 44.4±16.7 | 50.3±14.8 | 47.1±15.8 |
| 15–20 | 3 (100%) | 0 | 3 (7.3%) |
| 21–30 | 1 (25%) | 3 (75%) | 4 (9.8%) |
| 31–40 | 7 (63.6%) | 4 (39.4%) | 11 (26.9%) |
| 41–50 | 4 (44.5%) | 5 (55.5%) | 9 (21.9%) |
| 51–60 | 6 (66.7%) | 3 (33.3%) | 9 (21.9%) |
| 61–70 | 1 (33.3%) | 2 (66.7%) | 3 (7.3%) |
| >70 | 1 (50%) | 1 (50%) | 2 (4.9%) |
| pre-hypertension | 3 (7.3%) | 0 | 3 (7.3%) |
| stage 1 | 4 (9.8%) | 3 (7.3%) | 7 (17.1%) |
| stage 2 | 16 (39.0%) | 15 (36.6%) | 31 (75.6%) |
| 15–20 | 3 (7.9%) | 0 | 3 (7.9%) |
| 21–30 | 1(2.6%) | 3 (7.9%) | 4 (10.5%) |
| 31–40 | 6 (14.8%) | 4 (10.5%) | 10 (26.3%) |
| 41–50 | 3 (7.9%) | 5 (13.2%) | 8 (21.1%) |
| 51–60 | 5 (13.2%) | 3 (7.9%) | 8 (21.1%) |
| 61–70 | 1 (2.6%) | 2 (5.3%) | 3 (7.9%) |
| >71 | 1 (2.6%) | 1 (2.6%) | 2 (5.3%) |
| <20 | 2 (4.9%) | 5 (12.2%) | 7 (17.1%) |
| 20–29 | 14 (34.2%) | 9 (22.0%) | 23 (56.1%) |
| 30–39 | 7 (17.1%) | 4 (9.8%) | 11 (26.8%) |
| ≥40 | 0 | 0 | 0 |
SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; N, frequency; PCV, packed cell volume; TWCC, total white cell count; HD, haemodialysis; #median/range
Renal and extrarenal manifestations of ADPKD subjects in OAUTH Ile-Ife (1996–2010)
| Parameter | Total | Frequency by gender | |
| Nocturia | 32 (78%) | 19 | 13 |
| Frothy urine | 2 (4.9%) | 1 | 1 |
| Facial swelling | 25 (61%) | 12 | 13 |
| Body swelling | 10 (24.4%) | 4 | 6 |
| Loin pain | 28 (68.3%) | 16 | 12 |
| haematuria | 15 (36.6%) | 7 | 8 |
| LOC | 4 (9.8%) | 1 | 3 |
| Oliguria | 24 (58.5%) | 14 | 10 |
| Stroke | 4 (9.8%) | 2 | 2 |
| Pallor | 35 (85.4%) | 18 | 17 |
| Hypertension | 36 (87.8%) | 19 | 17 |
| Hepatomegaly | 4 (9.8%) | 1 | 3 |
| Nephromegaly | 34 (82.9%) | 18 | 7 |
| LVH | 35 (85.4%) | 18 | 17 |
| Uraemia | 24 (58.5%) | 14 | 10 |
| Splenomegaly | 1 (2.4%) | 0 | 1 |
| UTI | 13 (31.7%) | 6 | 7 |
| Cystic haemorrhage | 14 (34.2%) | 8 | 6 |
| Liver cysts | 13 (31.7%) | 6 | 7 |
| Splenic cyst | 1 (2.4%) | 0 | 1 |
| Pancreatic cyst | 2 (4.9%) | 1 | 1 |
| Aortic regurgitation | 9 (22%) | 4 | 5 |
| MVP | 0 | 0 | 0 |
| Cerebral | 6 (14.6%) | 3 | 3 |
| Aneurysm | |||
| Ovarian cyst | 0 | 0 | 0 |
LOC, loss of consciousness; LVH, left ventricular hypertrophy; UTI, urinary tract infection; MVP, mitral valve prolapsed
Figure 1KDOQI staging of ADPKD patients in OAUTH Ile-Ife (1996–2010) HD, haemodialysis; PD, peritoneal dialysis; RRT, renal replacement therapy
Annual incidence of ADPKD in OAUTH Ile-Ife (1996–2010)
| Year of | Male | Female | Total |
| 1996 | 0 | 1 | 1 (2.4%) |
| 1997 | 1 | 1 | 2 (4.8%) |
| 1998 | 1 | 1 | 2 (4.8%) |
| 1999 | 0 | 2 | 2 (4.8%) |
| 2000 | 0 | 1 | 1 (2.4%) |
| 2001 | 3 | 0 | 3 (7.5%) |
| 2002 | 3 | 0 | 3 (7.5%) |
| 2003 | 1 | 0 | 1 (2.4%) |
| 2004 | 0 | 2 | 2 (4.8%) |
| 2005 | 2 | 1 | 3 (7.8%) |
| 2006 | 3 | 4 | 7 (17.1%) |
| 2007 | 4 | 3 | 7 (17.1%) |
| 2008 | 3 | 1 | 4 (9.8%) |
| 2009 | 1 | 1 | 2 (4.8%) |
| 2010 | 1 | 0 | 1 (2.4%) |
| Total | 23 | 18 | 41 (100%) |
Figure 2Utilization of renal replacement therapy by ADPKD patients.
Factors contributing to mortality among ADPKD patients in OAUTH
| Mortality factors | Alive | Dead | p value (CI, 95%) |
| Uraemia | 6 | 18 | <0.01 |
| Ruptured cerebral aneurysm | 0 | 6 | 0.01 |
| Female gender | 9 | 9 | 0.89 |
| Male gender | 11 | 12 | 0.89 |
| Left ventricular hypertrophy | 15 | 20 | 0.067 |